Abstract: Provided is an optical imaging system, adapted for presenting an image of a particle. The optical imaging system includes a collimated light source, a flow channel, and a telecentric lens. The collimated light source is adapted for emitting a parallel beam. The flow channel is arranged on the transmission path of the parallel beam and is adapted for allowing the particle to pass through. The telecentric lens is arranged on the transmission path of the parallel beam. The parallel beam passes through the flow channel before transmitted to the telecentric lens, and the telecentric lens is adapted for converging the parallel beam onto an imaging plane.

Abstract: Pyrimidine compounds of Formula (I). Assignments to the variables in the formula are set forth herein. Also disclosed is a method of treating cancer with one of the pyrimidine compounds.

Abstract: Isolated antibodies that bind specifically to R-spondin 3 (RSPO3) are described. Also described herein are compositions containing the antibodies and methods of using the antibodies to treat cancer and detect RSPO3.

Abstract: Aspects of a cloud service framework are described. In some examples, a noncompliance event is received. The noncompliance event is identified using parameters detected from a deployment of hardware resources and software resources provided by a cloud service according to a service level agreement (SLA). An application programming interface (API) associated with the noncompliance event is identified. The API is disabled by updating an API availability status. A request to invoke the API is received, and the API is prevented from being forwarded to a backend service that provides the API.

Abstract: Disclosed herein is a specific crystalline forms of (S, E)-4-(dimethylamino)-N-(3-(4-(2-hydroxy-1-phenylethylamino)-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl)but-2-enamide (ABT-101) free base, the pharmaceutical composition and capsule comprising the same, and the medical application thereof. Said crystalline forms of ABT-101 free base can exhibit unexpected stability and improved pharmacokinetic properties compared to other forms or salt thereof, thereby allowing said compound more suitable for drug development and satisfying the requirements for bioavailability and drug efficacy.

Abstract: The present disclosure provides an electroplating method, comprising providing an electroplating solution, wherein the electroplating solution includes an effective microorganisms aqueous solution and metal chloride; disposing a workpiece, wherein at least a part of the workpiece is in contact with the electroplating solution; and performing an electroplating process to electroplate metal of the metal chloride onto the workpiece.

Abstract: Heterocyclic compounds of formula I shown below and pharmaceutical compositions containing one of such compounds: Also disclosed is a method of treating a condition modulated by the colony-stimulating factor-1 receptor with one of the heterocyclic compounds.

Abstract: A coin battery testing device, including a bottom base, an upper cover, a positive conducting structure, and a negative conducting structure, is provided. The bottom base has an observation region and is adapted to carry a coin battery by the observation region. The upper cover is detachably connected to the bottom base and adapted to cover the coin battery on the observation region. The upper cover has an opening and the opening corresponds to the observation region, such that the coin battery is adapted to be observed through the opening. The positive conducting structure is disposed on the bottom base and adapted to be connected to a positive electrode of the coin battery on the observation region. The negative conducting structure is disposed on the bottom base and adapted to be connected to a negative electrode of the coin battery on the observation region.

Abstract: The current disclosure describes a new vertical tunnel field-effect transistor (TFET). The TFET includes a source layer over a substrate. A first channel layer is formed over the source layer. A drain layer is stacked over the first channel layer with a second channel layer stacked therebetween. The drain layer and the second channel layer overlap a first surface portion of the first channel layer. A gate structure is positioned over the channel layer by a second surface portion of the channel layer and contacts a sidewall of the second channel layer.

Abstract: The current disclosure describes a new vertical tunnel field-effect transistor (TFET). The TFET includes a source layer over a substrate. A first channel layer is formed over the source layer. A drain layer is stacked over the first channel layer with a second channel layer stacked therebetween. The drain layer and the second channel layer overlap a first surface portion of the first channel layer. A gate structure is positioned over the channel layer by a second surface portion of the channel layer and contacts a sidewall of the second channel layer.

Abstract: A lithography-free, mold-free method of fabricating high quality optical material by curing polydimethylsiloxane (PDMS) droplets in or on pre-heated substrates allows lenses with different focal lengths to be made by varying the volume and surface temperature, as well as the substrate.

Abstract: A disposable patient isolation hood is provided and includes a frame and an isolation element, wherein the frame includes a base and a support bridge, and two ends of the support bridge are respectively connected to the first end portion and the second end portion of the base. The isolation element is flexible, and at least a part thereof is made of a transparent material. The isolation element is arranged to cover the support bridge to form a space that can encompass at least a part of the subject in need. The disposable patient isolation hood is easy to carry and has high mobility, so that medical practitioners can be isolated and protected during medical treatment of patients even in the absence of medical resources or in emergency situations.

Abstract: Compounds of Formula (I) shown below and a pharmaceutical composition containing one of the compounds: Each of the variables is defined herein. Also disclosed is a method of treating a condition associated with uncontrolled cell growth with a compound of Formula (I).

Abstract: The present disclosure relates to the fabrication and characterization of an optical fiber capable of firing light virtually from any point along its circumferential surface. The optical fiber is preferably prepared by laser micromachining. In preferred embodiments, laser radiation is focused onto a multimode optical fiber axis, forming a conical-shaped cavity (side window) in the fiber core. Because of the total internal reflection when the laser beam reaches the side window-outside medium interface, the beam is reflected to the side of the optical fiber.

Abstract: An isolated antibody, comprising a light-chain CDR1 (L-CDR1) having the sequence of SEQ ID NO: 1, SEQ ID NO: 7, or SEQ ID NO: 14; a light-chain CDR2 (L-CDR2) having the sequence of SEQ ID NO: 2 or SEQ ID NO: 15; a light-chain CDR3 (L-CDR3) having the sequence of SEQ ID NO: 3, SEQ ID NO: 8, SEQ ID NO: 21, or SEQ ID NO: 24; a heavy-chain CDR1 (H-CDR1) having the sequence of SEQ ID NO: 4, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 16, or SEQ ID NO: 25; a heavy-chain CDR2 (H-CDR2) having the sequence of SEQ ID NO: 5, SEQ ID NO: 12, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 22, or SEQ ID NO: 26; and a heavy-chain CDR3 (H-CDR3) having the sequence of SEQ ID NO: 6, SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 23, or SEQ ID NO: 27, wherein the antibody specifically binds to A?1-42 or an N-terminal modified form thereof.

Abstract: An isolated antibody, comprising: heavy chain complementary determining regions CDR1, CDR2, and CDR3 of a heavy chain variable region sequence selected from SEQ ID NOs: 2, 6, 10, and 14; and light chain complementary determining regions CDR1, CDR2, and CDR3 of a light chain variable region sequence selected from SEQ ID NOs: 4, 8, 12, and 16; wherein the antibody binds specifically to a RSPO3 protein.

Abstract: Embodiments provide data in-flight (DIF) services to software applications such as virtual machines (VMs) at an application level without requiring modification to established storage protocols. In exemplary embodiments, a storage controller transmits an advertisement of one or more data in-flight (DIF) services supported by a storage container of the storage controller. One or more DIF services communication path is created with attributes corresponding to the DIF services supported by the storage container. The storage controller receives, over the DIF services communication path, tagged data that can include data transmitted by a virtual machine (VM) for storage in the storage container.

Abstract: An operating circuit including a system circuit and a power control circuit is provided. The system circuit operates according to the voltage of the node. The power control circuit includes a first connection port, a second connection port, a first always-on switch, a second always-on switch, a first current limiter, and a second current limiter. The first connection port is configured to receive first power provided by a first external device. The second connection port is configured to receive second power provided by a second external device. The first always-on switch is coupled to the first connection port to transmit the first power. The second always-on switch is coupled to the second connection port to transmit the second power. The first current limiter is coupled between the first always-on switch and the node. The second current limiter is coupled between the second always-on switch and the node.

Abstract: A methodology for assays and diagnostics utilizes a nanoporous or corrugated metal-containing surface, fiber or particle which enhances or suppresses the optical detectability of a label. The resulting optical, electromagnetic, or imaging signal signals the presence of a pathogen or analyte of interest. Preferred embodiments pertain to label-free, in situ monitoring of individual DNA hybridization in microfluidics using molecular sentinel probes immobilized on nanoporous gold disks. By immobilizing molecular sentinel probes on nanoporous gold disks, single-molecule sensitivity is demonstrated via surface-enhanced Raman scattering which provides robust signals. The described methodology is generally applicable to most amplification independent assays and molecular diagnostics.

Abstract: A virtualization platform can discover capabilities of data devices connected in a virtual infrastructure. The virtualization platform allows a user (e.g., system administrator) to specify a policy profile for a virtual machine in terms of performance and data handling parameters. The virtualization platform can provision a virtual machine comprising data devices having a combined capability that matches the policy profile. Enforcement of a policy profile can be made when I/O is performed by a virtual machine.